vs
MESA LABORATORIES INC（MLAB）与万物新生（RERE）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是万物新生的1.5倍（$65.1M vs $43.2M），万物新生净利率更高（16.9% vs 5.6%，领先11.3%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
万物新生集团（ATRenew Inc.）是中国领先的二手消费电子产品交易与服务平台运营商，核心业务覆盖数码产品回收、质检、翻新及售卖，运营有爱回收等知名品牌，服务覆盖个人消费者及企业客户，市场遍及国内及部分东南亚地区。
MLAB vs RERE — 直观对比
营收规模更大
MLAB
是对方的1.5倍
$43.2M
净利率更高
RERE
高出11.3%
5.6%
损益表 — Q3 FY2026 vs Q1 FY2023
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $43.2M |
| 净利润 | $3.6M | $7.3M |
| 毛利率 | 64.2% | — |
| 营业利润率 | 12.2% | — |
| 净利率 | 5.6% | 16.9% |
| 营收同比 | 3.6% | — |
| 净利润同比 | 316.6% | — |
| 每股收益（稀释后） | $0.65 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABRERE
| Q4 25 | $65.1M | — | ||
| Q3 25 | $60.7M | — | ||
| Q2 25 | $59.5M | — | ||
| Q1 25 | $62.1M | — | ||
| Q4 24 | $62.8M | — | ||
| Q3 24 | $57.8M | — | ||
| Q2 24 | $58.2M | — | ||
| Q1 24 | $58.9M | — |
净利润MLABRERE
| Q4 25 | $3.6M | — | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $4.7M | — | ||
| Q1 25 | $-7.1M | — | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $3.4M | — | ||
| Q2 24 | $3.4M | — | ||
| Q1 24 | $-254.6M | — |
毛利率MLABRERE
| Q4 25 | 64.2% | — | ||
| Q3 25 | 61.5% | — | ||
| Q2 25 | 62.0% | — | ||
| Q1 25 | 61.8% | — | ||
| Q4 24 | 63.3% | — | ||
| Q3 24 | 61.3% | — | ||
| Q2 24 | 64.0% | — | ||
| Q1 24 | 62.1% | — |
营业利润率MLABRERE
| Q4 25 | 12.2% | — | ||
| Q3 25 | 7.8% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 9.2% | — | ||
| Q3 24 | 6.1% | — | ||
| Q2 24 | 9.6% | — | ||
| Q1 24 | -460.6% | — |
净利率MLABRERE
| Q4 25 | 5.6% | — | ||
| Q3 25 | 4.1% | — | ||
| Q2 25 | 8.0% | — | ||
| Q1 25 | -11.4% | — | ||
| Q4 24 | -2.7% | — | ||
| Q3 24 | 5.9% | — | ||
| Q2 24 | 5.8% | — | ||
| Q1 24 | -432.2% | — |
每股收益（稀释后）MLABRERE
| Q4 25 | $0.65 | — | ||
| Q3 25 | $0.45 | — | ||
| Q2 25 | $0.85 | — | ||
| Q1 25 | $-1.30 | — | ||
| Q4 24 | $-0.31 | — | ||
| Q3 24 | $0.63 | — | ||
| Q2 24 | $0.62 | — | ||
| Q1 24 | $-47.26 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $228.0M |
| 总债务越低越好 | $68.4M | — |
| 股东权益账面价值 | $186.7M | $557.1M |
| 总资产 | $434.8M | $722.9M |
| 负债/权益比越低杠杆越低 | 0.37× | — |
8季度趋势，按日历期对齐
现金及短期投资MLABRERE
| Q4 25 | $29.0M | — | ||
| Q3 25 | $20.4M | — | ||
| Q2 25 | $21.3M | — | ||
| Q1 25 | $27.3M | — | ||
| Q4 24 | $27.3M | — | ||
| Q3 24 | $24.3M | — | ||
| Q2 24 | $28.5M | — | ||
| Q1 24 | $28.2M | — |
总债务MLABRERE
| Q4 25 | $68.4M | — | ||
| Q3 25 | $69.4M | — | ||
| Q2 25 | $70.3M | — | ||
| Q1 25 | $71.3M | — | ||
| Q4 24 | $72.2M | — | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — | ||
| Q1 24 | — | — |
股东权益MLABRERE
| Q4 25 | $186.7M | — | ||
| Q3 25 | $178.5M | — | ||
| Q2 25 | $172.5M | — | ||
| Q1 25 | $159.8M | — | ||
| Q4 24 | $155.2M | — | ||
| Q3 24 | $161.5M | — | ||
| Q2 24 | $150.7M | — | ||
| Q1 24 | $145.4M | — |
总资产MLABRERE
| Q4 25 | $434.8M | — | ||
| Q3 25 | $430.4M | — | ||
| Q2 25 | $435.7M | — | ||
| Q1 25 | $433.3M | — | ||
| Q4 24 | $433.3M | — | ||
| Q3 24 | $454.1M | — | ||
| Q2 24 | $440.4M | — | ||
| Q1 24 | $446.8M | — |
负债/权益比MLABRERE
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | — |
| 自由现金流经营现金流 - 资本支出 | $18.0M | — |
| 自由现金流率自由现金流/营收 | 27.7% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | 5.17× | — |
| 过去12个月自由现金流最近4个季度 | $37.9M | — |
8季度趋势，按日历期对齐
经营现金流MLABRERE
| Q4 25 | $18.8M | — | ||
| Q3 25 | $8.2M | — | ||
| Q2 25 | $1.9M | — | ||
| Q1 25 | $12.7M | — | ||
| Q4 24 | $18.1M | — | ||
| Q3 24 | $5.3M | — | ||
| Q2 24 | $10.7M | — | ||
| Q1 24 | $12.9M | — |
自由现金流MLABRERE
| Q4 25 | $18.0M | — | ||
| Q3 25 | $7.1M | — | ||
| Q2 25 | $884.0K | — | ||
| Q1 25 | $11.9M | — | ||
| Q4 24 | $17.3M | — | ||
| Q3 24 | $3.5M | — | ||
| Q2 24 | $9.9M | — | ||
| Q1 24 | $12.3M | — |
自由现金流率MLABRERE
| Q4 25 | 27.7% | — | ||
| Q3 25 | 11.7% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 19.2% | — | ||
| Q4 24 | 27.6% | — | ||
| Q3 24 | 6.0% | — | ||
| Q2 24 | 16.9% | — | ||
| Q1 24 | 21.0% | — |
资本支出强度MLABRERE
| Q4 25 | 1.1% | — | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.1% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 0.9% | — |
现金转化率MLABRERE
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 3.17× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
RERE
暂无分部数据
